Originally approved by IARC on March 9, 2018.

“The sequence was inferred by Martin Corcoran using IgDiscover, and by Duncan Ralph using both Partis and TIgGER. The number of unique CDR3 used by sequences with exact matches to the inferred germline allele represents 1.9% [NOTE: 1.77% using the herein used approach to define number of exact matches] of all unique CDR3 associated to exact IGHV matches in the genotype,according to IgDiscover. There were at least 739 unique rearrangements, utilizing 19 D genes and 7 J genes, and hundreds of exact matches. The allele was the more frequently utilized allele, with an expression ratio of 70:30 with the *01 allele. The inference was supported by haplotype analysis using IGHJ6*02/*03. The sequence is present in the IgPdb as IGHV1-2*p06. The full length sequence was first reported to IgPdb in 2015 by Scheepers and colleagues (see J Immunol 194:4371-8) from genomic sequencing, and it was separately reported to IgPdb in 2016 by Kirik and colleagues (see Mol Immunol 87:12-22), as an inference from VDJ rearrangements.”

In line with IARC policy, the submitted sequence was recognized up to and including nucleotide 319.

(April 12, 2019) A trailing “.” in the sequence indicates IARC’s opinion that the sequence is likely to contain additional 3’ nucleotides for which there is insufficient evidence to make an affirmation.

The allele was incorporated into IMGT on July 24, 2018 as IGHV1-2*06.